Markets:
DJIA +112.640.33%
NASDAQ +78.060.71%
S&P +15.920.40%
Featured Stocks:
LIT 0.83% 64.44
DOUG +1.15% 4.39
RIG +3.85% 5.66

how to invest

Article Index

Stash vs. Robinhood: The Definitive Review

By , Money Morning -

Traders, from the most casual to the most serious, are piling into investing apps.

Robinhood and Stash have been two of the biggest winners over the last year.

The Robinhood app alone added 3 million new users in the first quarter of 2020.

But which is better? We'll show you which comes out ahead in the Stash v.

Robinhood matchup.

They're quick, easy, and most of all, they give traders access to profit.

10 Best Investment Apps That Aren’t Robinhood

By , Associate Editor, Money Morning -

Swarms of new investors jumped into the market in the first quarter of 2020.

Mobile investment apps grew their new accounts by as much as 170%.

Whether you're a new or experienced investor, there's probably a platform for you.

Robinhood is among the best.

But there could be one or two with tools better suited for where you are in your investing career.

Let's look at some of the best investment apps that aren't Robinhood.

Read more...

How Broker Fees Crush Your Profits, and What to Do About It

By , Associate Editor, Money Morning • @DavidGZeiler -

Broker Fees

Many investors don't give much thought to broker fees, but they should.

Depending on your personal situation, broker fees could be draining as much as one-third of your long-term profits. You can minimize fees with strategies like using a discount broker, but no investor can eliminate them completely.

But there's something more you can do to claw back some of your lost profits.

You can take a page from the broker's book...

How to Protect Your Biotech Profits from This Legal Limbo

By , Biotech Investing Specialist, Money Morning -

biotech profits

Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.

Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long - 24 to 48 weeks - and arduous.

Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.

Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.

So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.

There's just one big, expensive problem...

The Ultimate Must-Have Investment

By , Chief Investment Strategist, Money Map Report -

investment stocks

The "ultimate must-have investment" is a profit play that, when executed correctly, can't fail, but not one in a million investors has thought about it, let alone knows how to play it for maximum profits.

The situation is so lopsided, in fact, that I'd venture a guess that 99.99% of all investors could quadruple their allocation to this particular must-have opportunity and still not have enough.

Which makes this an even bigger opportunity for you...